Loading...
•
Jun 30, 2021
Adicet Bio Q2 2021 Earnings Report
Reported operational highlights and financial results.
Key Takeaways
Adicet Bio reported its Q2 2021 financial results, highlighting the initiation of the Phase 1 trial of ADI-001 in non-Hodgkin’s lymphoma and the completion of a successful capital raise. The company's cash position is expected to fund operations through the beginning of the second half of 2023.
Initiated Phase 1 trial of ADI-001 in non-Hodgkin’s lymphoma.
Completed a successful capital raise.
Established a Scientific Advisory Board (SAB).
Added to the Russell 2000® Index.
Forward Guidance
Adicet expects that current cash, cash equivalents and marketable securities as of June 30, 2021 will be sufficient to fund its operating expenses through the beginning of the second half of 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...